As previously reported, Wolfe Research initiated coverage of Verona Pharma (VRNA) with an Outperform rating and $170 price target Newly commercialized Chronic Obstructive Pulmonary Disease treatment Ohtuvayre has had a “strong performance” in its first few quarters since its launch, says the analyst, who estimates Verona’s Ohtuvayre opportunity to be between 173,000 to 224,000 patients, which translates to about a $6.1B-$8B peak opportunity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma initiated with an Outperform at Wolfe Research
- Verona Pharma price target raised to $160 from $76 at Piper Sandler
- Verona Pharma price target raised to $138 from $107 at Wells Fargo
- Strong Buy Rating for Verona Pharma’s Ohtuvayre Amidst Undervalued Peak Sales Potential and Growing Market Demand
- Verona Pharma price target raised to $116 from $92 at Roth Capital